Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fennec Pharmaceuticals Inc. (FENC) on December 5, 2023, reporting events occurring on December 4, 2023. The filing details the closing of a third tranche of financing and an amendment to the existing Securities Purchase Agreement (SPA) with Petrichor Opportunities Fund I LP.
Key Financial Metrics and Debt Structure
- Financing Amount: The Company closed a third tranche of $5,000,000 in senior secured floating rate convertible notes.
- Total Facility: The SPA allows for up to $45,000,000 in total issuance. Prior tranches of $5,000,000 and $20,000,000 were closed in August and September 2022, respectively.
- Remaining Capacity: $15,000,000 remains available under the amended agreement.
- Interest Rate: The notes accrue interest at the greater of the US Prime Rate or 3.5%, plus a 4.5% margin. Interest is payable quarterly.
- Payment Terms: For the first 12 months following the closing date, all interest is paid-in-kind (PIK).
- Conversion Price: Notes are convertible into common shares at $7.89 per share.
- Maturity Date: August 19, 2027.
Material Changes and Amendments
The Company entered into a First Amendment to the SPA on December 4, 2023. The primary material change is the extension of the deadline to draw the remaining $15,000,000 under the facility from December 31, 2023, to December 31, 2024. Subsequent draws are subject to mutual agreement between the Company and the Investor.
Outlook, Risks, and Covenants
- Redemption Rights: The Company may redeem the notes after August 19, 2025, at a premium of 110% (prior to Aug 2026) or 107.5% (after Aug 2026).
- Default Provisions: Upon certain events of default or a change of control, the holder may require redemption at the applicable premium. Bankruptcy-related defaults trigger automatic acceleration of principal and interest.
- Covenants: The notes restrict the Company from incurring additional indebtedness (except permitted), permitting liens, paying dividends, or transferring assets. The Company must also maintain a minimum amount of unrestricted cash.
- Liquidity Impact: The filing does not provide specific cash flow or liquidity metrics beyond the new debt obligation and the requirement to maintain minimum unrestricted cash.
Investor Verification Checklist
- Verify the total outstanding principal balance of the Notes following the $5,000,000 third closing.
- Confirm the Company's current unrestricted cash balance to ensure compliance with the minimum cash covenant.
- Review the full text of the Third Closing Note (Exhibit 4.1) and SPA Amendment (Exhibit 10.1) for specific definitions of "permitted indebtedness" and "events of default."
- Assess the dilution impact of the $7.89 conversion price relative to the current trading price of FENC common shares.
- Monitor the Company's ability to service the PIK interest obligation over the next 12 months.